← Back to Screener
Assembly Biosciences, Inc (ASMB)
Price$29.32
Favorite Metrics
Price vs S&P 500 (26W)12.92%
Price vs S&P 500 (4W)2.50%
Market Capitalization$472.87M
All Metrics
Book Value / Share (Quarterly)$11.55
P/TBV (Annual)0.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)65.83%
Cash Flow / Share (Quarterly)$-3.53
Price vs S&P 500 (YTD)-14.99%
Net Profit Margin (TTM)-103.65%
EPS (TTM)$-4.81
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-4.81
Revenue Growth (5Y)12.31%
EPS (Annual)$-6.69
ROI (Annual)-120.44%
Net Profit Margin (5Y Avg)-752.44%
Cash / Share (Quarterly)$14.70
Revenue Growth QoQ (YoY)57.62%
ROA (Last FY)-33.71%
Revenue Growth TTM (YoY)31.30%
EBITD / Share (TTM)$-5.04
ROE (5Y Avg)-96.95%
Operating Margin (TTM)-116.83%
Cash Flow / Share (Annual)$-6.86
P/B Ratio2.59x
P/B Ratio (Quarterly)2.22x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)12.11x
Net Interest Coverage (TTM)-99.13x
ROA (TTM)-28.61%
EPS Incl Extra (Annual)$-6.69
Current Ratio (Annual)2.42x
Quick Ratio (Quarterly)4.37x
3-Month Avg Trading Volume0.11M
52-Week Price Return192.25%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$42.13
P/S Ratio (Annual)16.58x
Asset Turnover (Annual)0.24x
52-Week High$39.70
Operating Margin (5Y Avg)-781.75%
EPS Excl Extra (Annual)$-6.69
CapEx CAGR (5Y)-55.21%
Tangible BV CAGR (5Y)27.13%
26-Week Price Return16.90%
Quick Ratio (Annual)2.34x
13-Week Price Return-3.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.44x
Enterprise Value$450.333
Revenue / Share Growth (5Y)-8.23%
Asset Turnover (TTM)0.28x
Book Value / Share Growth (5Y)-46.36%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-139.72%
Cash / Share (Annual)$15.03
3-Month Return Std Dev59.48%
Net Income / Employee (TTM)$-1
ROE (Last FY)-120.44%
Net Interest Coverage (Annual)-98.91x
EPS Basic Excl Extra (Annual)$-6.69
Receivables Turnover (TTM)81.56x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.81
Receivables Turnover (Annual)1326.51x
ROI (TTM)-59.01%
P/S Ratio (TTM)12.71x
Pretax Margin (5Y Avg)-761.18%
Revenue / Share (Annual)$4.75
Tangible BV / Share (Annual)$42.13
Price vs S&P 500 (52W)162.42%
Year-to-Date Return-12.35%
5-Day Price Return-0.13%
EPS Normalized (Annual)$-6.69
ROA (5Y Avg)-51.96%
Net Profit Margin (Annual)-140.87%
Month-to-Date Return7.42%
Cash Flow / Share (TTM)$-1.41
EBITD / Share (Annual)$-7.54
Operating Margin (Annual)-159.26%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-96.95%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.81
P/TBV (Quarterly)0.66x
P/B Ratio (Annual)3.01x
Pretax Margin (TTM)-103.85%
Book Value / Share (Annual)$4.47
Price vs S&P 500 (13W)-4.31%
Beta1.20x
P/FCF (Annual)21.03x
Revenue / Share (TTM)$2.93
ROE (TTM)-59.01%
52-Week Low$9.37
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.30
4.30
4.30
4.30
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ASMBAssembly Biosciences, Inc | 12.71x | 31.30% | — | — | $29.32 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Assembly Biosciences is a clinical-stage biotechnology company developing two oral therapeutic platforms: one targeting hepatitis B virus (HBV) infection, and another addressing microbiome dysbiosis. Its lead HBV program employs proprietary core protein Allosteric Modulators—small molecules that inhibit multiple steps of the viral lifecycle to improve cure rates beyond current clinical standards. The HBV program constitutes the majority of the company's revenue.